Scholarlink

Background <p>Cytomegalovirus (CMV) colitis and <i>Clostridioides difficile</i> infection (CDI) are both linked to disease exacerbation and poor prognosis in patients with inflammatory bowel disease (IBD). Nonetheless, the effect of co-infection on clinical outcomes in individuals with IBD remains underexplored. This retrospective study was designed to assess the clinical outcomes and determine predictors of co-infection with CMV and CDI in individuals with IBD.</p> Methods <p>This analysis involved hospitalized patients with IBD and confirmed CMV colitis (based on intestinal CMV immunohistochemical staining) and <i>Clostridioides difficile</i> toxin A/B test results, collected at the Linkou branch of Chang Gung Memorial Hospital between January 2001 and September 2023. The individuals in the study cohort were divided into two categories: those with CMV infection alone and those with CMV/CDI co-infection. Clinical manifestations, outcomes, and independent predictors of co-infection were assessed between the two groups.</p> Results <p>Overall, 53 IBD inpatients were enrolled in this study, with 37 assigned to the CMV group and 16 to the CMV/CDI co-infection group. The co-infection group experienced significantly more diarrhea (54.1% vs. 93.8%, <i>p</i> = 0.005) and abdominal pain (54.1% vs. 87.5%, <i>p</i> = 0.020) compared to the CMV group. Hospitalization duration (1 vs. 2.5 admissions, <i>p</i> = 0.005) and CMV recurrence (0 vs. 1 recurrences, <i>p</i> &lt; 0.001) were higher in the co-infection group. Additionally, co-infection prolonged the time to clinical (1 vs. 5&#xa0;months, <i>p</i> &lt; 0.001), steroid-free (4 vs. 10&#xa0;months, <i>p</i> = 0.001), endoscopic (8.3 vs. 17.5&#xa0;months, <i>p</i> = 0.011), and histological remission (11 vs. 18&#xa0;months, <i>p</i> = 0.021) compared to CMV infection alone. The cumulative incidence of clinical, steroid-free, endoscopic, and histological remission showed a delayed course in the co-infection group. Multivariable analysis revealed that biologic therapy was an independent predictor for CMV/CDI co-infection (OR 13.33, 95% CI 1.52–117.15, <i>p</i> = 0.02).</p> Conclusion <p>Co-infection of CMV and CDI among individuals with IBD results in more frequent hospitalizations, higher CMV recurrence rates, and prolonged disease remission compared to CMV colitis alone. The administration of biologic therapy increases the risk of co-infection, emphasizing the importance of careful management in this patient population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clostridioides difficile co-infection worsens prognosis in inflammatory bowel disease in patients with cytomegalovirus colitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月23日

查看全文
  • Ching-Reigh Hsieh,
  • Chyi-Liang Chen,
  • Chia-Jung Kuo,
  • Ren-Chin Wu,
  • Pai-Jui Yeh,
  • Chien-Ming Chen,
  • Cheng-Tang Chiu,
  • Cheng-Hsun Chiu,
  • Ming-Yao Su,
  • Ming-Ling Chang,
  • Yuan-Ming Yeh,
  • Yu-Bin Pan,
  • Puo-Hsien Le

摘要

Background

Cytomegalovirus (CMV) colitis and Clostridioides difficile infection (CDI) are both linked to disease exacerbation and poor prognosis in patients with inflammatory bowel disease (IBD). Nonetheless, the effect of co-infection on clinical outcomes in individuals with IBD remains underexplored. This retrospective study was designed to assess the clinical outcomes and determine predictors of co-infection with CMV and CDI in individuals with IBD.

Methods

This analysis involved hospitalized patients with IBD and confirmed CMV colitis (based on intestinal CMV immunohistochemical staining) and Clostridioides difficile toxin A/B test results, collected at the Linkou branch of Chang Gung Memorial Hospital between January 2001 and September 2023. The individuals in the study cohort were divided into two categories: those with CMV infection alone and those with CMV/CDI co-infection. Clinical manifestations, outcomes, and independent predictors of co-infection were assessed between the two groups.

Results

Overall, 53 IBD inpatients were enrolled in this study, with 37 assigned to the CMV group and 16 to the CMV/CDI co-infection group. The co-infection group experienced significantly more diarrhea (54.1% vs. 93.8%, p = 0.005) and abdominal pain (54.1% vs. 87.5%, p = 0.020) compared to the CMV group. Hospitalization duration (1 vs. 2.5 admissions, p = 0.005) and CMV recurrence (0 vs. 1 recurrences, p < 0.001) were higher in the co-infection group. Additionally, co-infection prolonged the time to clinical (1 vs. 5 months, p < 0.001), steroid-free (4 vs. 10 months, p = 0.001), endoscopic (8.3 vs. 17.5 months, p = 0.011), and histological remission (11 vs. 18 months, p = 0.021) compared to CMV infection alone. The cumulative incidence of clinical, steroid-free, endoscopic, and histological remission showed a delayed course in the co-infection group. Multivariable analysis revealed that biologic therapy was an independent predictor for CMV/CDI co-infection (OR 13.33, 95% CI 1.52–117.15, p = 0.02).

Conclusion

Co-infection of CMV and CDI among individuals with IBD results in more frequent hospitalizations, higher CMV recurrence rates, and prolonged disease remission compared to CMV colitis alone. The administration of biologic therapy increases the risk of co-infection, emphasizing the importance of careful management in this patient population.